NCT05997017 - Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

October 31, 2026

Conditions

Endometrial CancerEndometrioid TumorCancerTumorRecurrent Endometrial CarcinomaEndometrioid Endometrial Cancer

Interventions

DRUG

nab-sirolimus

Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients

Trial Locations (9)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Levine Cancer Institute, Charlotte

RECRUITING

Mount Sinai Comprehensive Cancer Center, Miami Beach

RECRUITING

Michael Birrer, MD, PhD, Little Rock

RECRUITING

Oklahoma University Stephenson Cancer Center, Oklahoma City

RECRUITING

Texas Oncology - Tyler, Tyler

RECRUITING

Women's Cancer Center of Nevada, Las Vegas

RECRUITING

Swedish Cancer Institute, Seattle

RECRUITING

Women & Infants Hospital, Providence